Nuvation Bio Inc. (NUVB) Earnings
Nuvation Bio Inc. is expected to report next earnings on August 6, 2026 (in NaN days), with a consensus EPS estimate of $-0.15. NUVB has beaten EPS estimates in 4 of its last 12 reported quarters (average surprise -24.7% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 4, 2026 | $0.12 | $0.01 | -91.7% | $83M | +25.7% |
| Aug 7, 2025 | $-0.17 | $-0.17 | +0.0% | $5M | +33.4% |
| May 7, 2025 | $-0.16 | $-0.16 | +0.0% | $3M | +763.5% |
| Mar 6, 2025 | $-0.14 | $-0.15 | -7.1% | $6M | +585.3% |
| Feb 29, 2024 | $-0.10 | $-0.06 | +40.0% | $264000 | — |
| Nov 2, 2023 | $-0.10 | $-0.09 | +10.0% | — | — |
| Aug 3, 2023 | $-0.11 | $-0.09 | +18.2% | — | — |
| May 4, 2023 | $-0.09 | $-0.10 | -11.1% | — | — |
| Mar 15, 2023 | $-0.10 | $-0.10 | +0.0% | — | — |
| Nov 3, 2022 | $-0.14 | $-0.12 | +14.3% | — | — |
| Aug 4, 2022 | $-0.13 | $-0.16 | -23.1% | — | — |
| Feb 28, 2022 | $-0.12 | $-0.12 | +0.0% | — | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 4, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Ibtrozi: Following FDA approval in June 2025, focused on commercial launch in ROS1-positive non-small cell lung cancer. Successfully treated ~200 new patients in Q1, three consecutive quarters of ~200 new patient starts, total over 600 since launch. Increasing trend of more new patients from first-line setting. Ibtrozi extended median duration of response to 50 months in TKI-naive patients. Added to CNS-NCCN guidelines as systemic therapy option for ROS1-positive NSCLC with brain metastases. Presented updated data at AACR reinforcing its profile. - Safucitinib: Evaluated in Phase III SIGMA study for maintenance treatment of IDH1 mutant glioma. Shown encouraging efficacy signals in phase one and two studies. Acquired exclusive rights to safucitinib in Japan from Daiichi Sankyo. - Commercial efforts: Strong momentum in Ibtrozi launch. 97% aided awareness among target physicians. 100% of top 50 historical TKI accounts have prescribed Ibtrozi. Implemented initiatives to improve testing rates in community centers.
Guidance
- Expect Ibtrozi net product revenue trend to continue growing as more U.S. physicians become aware and testing rates improve. - Anticipate milestone payment of ~$30 million from ASI upon Ibtrozi's approval in Europe in H1 2027. - Believe current capital position provides flexibility to support Ibtrozi launch, advance pipeline, and evaluate strategic opportunities without additional external financing.
Segment performance
In the first quarter of 2026, total revenue was $83.2 million. Ibtrozi net U.S. product revenue was $18.5 million, representing 18% growth from the prior quarter. Collaboration and license revenue was $64.7 million, including an upfront payment of nearly $60 million from ASI. Operating expenses were $73.5 million, with R&D expenses at $35 million and SG&E expenses at $38.3 million. Cash, cash equivalents, and marketable securities ended the quarter at $533.7 million.
Analyst Q&A
Q: Comment on whether growing first-line patients are coming from academic or community setting and specific educational field force initiatives to accelerate adoption in high-volume community setting.
A: Colleen Sjogren said about 97% awareness across academic and community, 100% of top 50 historical TKI accounts have prescribed. Focused on testing rates, partnering with community oncology practices, investing in educational initiatives, working with testing platforms to ensure comprehensive molecular testing is standard.
Q: Follow up on new patient starts dynamic.
A: David Hung explained early quarters had mainly late-line patients who drop out quickly, new patients are newly diagnosed first-line patients, which take longer, and now seeing more first-line patients with trend expected to stabilize as late-line pool is depleted.
Q: Question on repeat prescription, CNS guideline inclusion help, and testing rates hurdles.
A: Colleen Sjogren said 100% of top 50 accounts prescribed, NCCN CNS guidelines important as Ibtrozi has CNS coverage and better profile than crizotinib. Testing rates improved with educational efforts on effective testing.
Q: Competitor data on activity in patients previously treated with Taltratinib.
A: David Hung said Ibtrozi has better efficacy in first and second line settings, competitor data in third line setting is welcome as patients need options, and Ibtrozi got breakthrough designation in first and second line.
Q: Development of new CNS meds relevance, discontinuations in frontline vs later lines.
A: David Hung said CNS important as ROS1 lung cancer is aggressive with brain metastasis, Ibtrozi has high intracranial response rate. Discontinuations in later lines are due to advanced disease, frontline patients have good tolerability.
Q: Sense of percentage of treatment naive patients, gross to net.
A: Yarin Verber was told first-line patients increasing quarter to quarter, gross to net expected to stabilize around 30% level.
Q: Duration of therapy in first-line patients compare to expectation, impact of NCCN guidelines, annual sales guidance.
A: Boris Peeker was told duration expected over four years, NCCN guidelines impact may be appreciated earlier, and may issue annual sales guidance in future.
Q: IDH1 program standard of care, PFS clinically meaningful, nearer-term milestones.
A: David Hung said standard of care is surgery, radiation, chemo. Response rates north of 20% would be meaningful, anything in that range could be approvable pathway.